The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous ...

Vericiguat (Merck/Bayer), among the latest drugs to gain cred in heart failure (HF) with reduced ejection fraction (HFrEF), significantly benefits patients who are highly adherent to standard-of-care ...

Vericiguat reduced the risk of cardiovascular mortality, heart failure (HF) hospitalizations and all-cause mortality across a broad range of patients with HF and reduced ejection fraction (HFrEF), ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the VICTORIA trial, a Phase 3 study evaluating ...

Treatment with the novel agent vericiguat (Merck Sharp & Dohme and Bayer), a drug that targets cyclic guanosine monophosphate (cGMP), significantly reduces the risk of cardiovascular mortality or ...

Novel oral agent vericiguat modestly reduced mortality and hospitalization among recently decompensated heart failure with reduced ejection fraction (HFrEF) patients in the pivotal VICTORIA trial.

The investigational oral soluble guanylate-cyclase (sGC) stimulator vericiguat (Bayer/Merck), under development for treating worsening chronic heart failure (HF), met the primary efficacy endpoint in ...

Nine out of 10 hospitalized patients who have heart failure with reduced ejection fraction (HFrEF) may be potential candidates for the novel agent vericiguat (Merck Sharp & Dohme/Bayer) to lower their ...

MADRID -- Vericiguat (Verquvo) missed the mark for reducing heart failure (HF) hospitalizations but lowered the risk of cardiovascular death in patients with HF with reduced ejection fraction (HFrEF) ...

Vericiguat did not reduce the risk of cardiovascular mortality and heart failure (HF) hospitalizations in ambulatory patients with HF and reduced ejection fraction (HFrEF) without recent worsening, ...